CLINICAL TRIALS PROFILE FOR XELJANZ XR
✉ Email this page to a colleague
All Clinical Trials for XELJANZ XR
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01932372 ↗ | Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis | Completed | Pfizer | 2013-07-26 | The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group. | |
| NCT02157012 ↗ | Evaluation of the Condition of Rheumatoid Arthritis After Treatment | Recruiting | Showa Inan General Hospital | Phase 4 | 2014-05-01 | To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients |
| NCT02157012 ↗ | Evaluation of the Condition of Rheumatoid Arthritis After Treatment | Recruiting | Shinshu University | Phase 4 | 2014-05-01 | To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients |
| NCT02299297 ↗ | Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis | Completed | Locks of Love | Phase 2 | 2015-01-01 | This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator. |
| NCT02299297 ↗ | Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis | Completed | Columbia University | Phase 2 | 2015-01-01 | This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator. |
| NCT02299297 ↗ | Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis | Completed | Julian M. Mackay-Wiggan | Phase 2 | 2015-01-01 | This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator. |
| NCT02312882 ↗ | Tofacitinib for the Treatment of Alopecia Areata and Its Variants | Completed | Stanford University | N/A | 2014-12-01 | The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XELJANZ XR
Condition Name
Clinical Trial Locations for XELJANZ XR
Trials by Country
Clinical Trial Progress for XELJANZ XR
Clinical Trial Phase
Clinical Trial Sponsors for XELJANZ XR
Sponsor Name
